Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 2, 2025
Product Development
VEGF bispecifics make inroads in other cancers, and more: Clinical Report
Plus: The week’s gainers and decliners after data
BioCentury | Mar 25, 2025
Finance
Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast
How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Mar 7, 2025
Product Development
Could amylin outshine GLP-1 in obesity?
If the preclinical data translate to the clinic, amylin has a good chance to supplant GLP-1 for the overweight to moderate obesity population
BioCentury | Mar 5, 2025
Data Byte
GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24
Sales of top brands from both Lilly and Novo recorded all-time highs, again
BioCentury | Mar 4, 2025
Product Development
CRISPR lessons; plus AbbVie enters obesity — a BioCentury podcast
BioCentury’s editors also discuss recommendations for early stage rare disease drug development
BioCentury | Feb 6, 2025
Product Development
Novo believes new CagriSema trial can hit weight loss goal
Aims to drive additional weight loss after analysis of Phase III REDEFINE 1 obesity data
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | Jan 25, 2025
Product Development
Amylin is back with Novo’s positive amycretin data
Injectable amycretin shows 24% placebo-adjusted weight loss, giving it the lead in efficacy — at least for now
Items per page:
1 - 10 of 50